Linked Life Data

1587961

Source:http://linkedlifedata.com/resource/pubmed/id/1587961

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1992-6-23
pubmed:abstractText
Selected adverse events were evaluated from the combined randomized placebo-controlled clinical trials (once-a-day or twice-a-day; monotherapy or combination therapy) of terazosin in hypertensive patients. The designs of these clinical trials were either titration to response or titration to a fixed dose. A grouped survival methodology using logistic regression, developed by Hosmane et al, was used to study the effects of age and dose on the incidence of adverse events. The analysis indicated that except for palpitations, nausea, headache, and dizziness the incidence of adverse events was not significantly related to either age or dose. Palpitations and headache decreased with increasing age and increasing dose and age, respectively. Dizziness and nausea increased at the maximum dose of 20 mg, but not at the 5- or 10-mg doses.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0091-2700
pubmed:author
pubmed:issnType
Print
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
434-43
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosin.
pubmed:affiliation
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064.
pubmed:publicationType
Journal Article